Literature DB >> 8646130

Designing a vaccine for tuberculosis.

A S Malin, D B Young.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8646130      PMCID： PMC2351265          DOI： 10.1136/bmj.312.7045.1495

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  16 in total

Review 1.  Modern vaccines. Mycobacterial diseases.

Authors:  P E Fine; L C Rodrigues
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

2.  Mutation of the principal sigma factor causes loss of virulence in a strain of the Mycobacterium tuberculosis complex.

Authors:  D M Collins; R P Kawakami; G W de Lisle; L Pascopella; B R Bloom; W R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

3.  Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis.

Authors:  M A Horwitz; B W Lee; B J Dillon; G Harth
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

4.  Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity.

Authors:  P E Fine; J A Sterne; J M Pönnighaus; R J Rees
Journal:  Lancet       Date:  1994-11-05       Impact factor: 79.321

5.  Bacillus Calmette-Guérin infection after vaccination of human immunodeficiency virus-infected children.

Authors:  M Besnard; S Sauvion; C Offredo; J Gaudelus; J L Gaillard; F Veber; S Blanche
Journal:  Pediatr Infect Dis J       Date:  1993-12       Impact factor: 2.129

6.  A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis.

Authors:  C L Silva; D B Lowrie
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

7.  Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins.

Authors:  P Andersen
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

Review 8.  Tuberculosis: commentary on a reemergent killer.

Authors:  B R Bloom; C J Murray
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

9.  Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis.

Authors:  G G Mahairas; P J Sabo; M J Hickey; D C Singh; C K Stover
Journal:  J Bacteriol       Date:  1996-03       Impact factor: 3.490

Review 10.  New concepts for the control of tuberculosis in the twenty first century.

Authors:  J L Stanford; J M Grange
Journal:  J R Coll Physicians Lond       Date:  1993-07
View more
  4 in total

1.  Association of interleukin-10 cytokine expression status with HLA non-DRB1*02 and Mycobacterium bovis BCG scar-negative status in south Indian pulmonary tuberculosis patients.

Authors:  V Dheenadhayalan; S Shanmugalakshmi; S Vani; P Muthuveeralakshmi; G Arivarignan; A D Nageswari; R M Pitchappan
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

2.  B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis.

Authors:  M Harboe; A S Malin; H S Dockrell; H G Wiker; G Ulvund; A Holm; M C Jørgensen; P Andersen
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

Review 3.  Zoonotic tuberculosis due to Mycobacterium bovis in developing countries.

Authors:  O Cosivi; J M Grange; C J Daborn; M C Raviglione; T Fujikura; D Cousins; R A Robinson; H F Huchzermeyer; I de Kantor; F X Meslin
Journal:  Emerg Infect Dis       Date:  1998 Jan-Mar       Impact factor: 6.883

Review 4.  Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker?

Authors:  Sarman Singh; Manoj Kumar; Pragati Singh
Journal:  Tuberc Res Treat       Date:  2015-01-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.